🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gita A. Toyserkani

United States Food and Drug Administration

ORCID: 0000-0002-6946-6138

Also affiliated with Center for Drug Evaluation and Research

Economics, Econometrics and FinancePharmacology, Toxicology and PharmaceuticsMedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020”.

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3
N/A
0DataRank · unranked
6 citations

Ameet Sarpatwari, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani +6 more

REMS Logic Model: A Pragmatic Framework for Incorporating Drug Safety into Clinical Practice

Drug Safety(2025)10.1007/s40264-025-01542-9
N/A
0DataRank · unranked
2 citations

Suzanne B Robottom, Elaine H. Morrato, Gita A. Toyserkani

Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials

Drug Safety(2025)10.1007/s40264-025-01636-4
N/A
0DataRank · unranked
0 citations

Carol Cosenza, Aaron S. Kesselheim, Gita A. Toyserkani, Kate Heinrich Oswell, Cynthia LaCivita +3 more